SI Stock Forecast & Price Target

Shoulder Innovations Inc demonstrated significant growth in 2Q25 by adding a higher number of surgeons than anticipated, with an adjusted forward growth estimate of approximately 11 new Core Contender surgeons per quarter. The company's total revenue reached $11.8 million, representing a 58% increase and surpassing estimates by $1.8 million, fueled by stronger than expected average selling prices (ASPs). With an enhanced balance sheet and substantial market opportunities, Shoulder Innovations is positioned to continue expanding its commercial efforts and driving top-line growth in the upcoming periods.

Shoulder Innovations Inc. is experiencing significant financial challenges, as evidenced by an adjusted EBITDA loss of $7.5 million, which exceeded expectations by approximately $400,000. The company's growth potential is hindered by factors such as slower product adoption among surgeons, lower overall shoulder market growth rates, and greater-than-expected operating expenses, contributing to a cumulative EBITDA loss of $35.9 million. Despite possessing a clinically validated product with zero revisions reported over a decade, the combination of market dynamics and increased costs has led to a negative outlook for the company's financial performance.